SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274: 214914.
  • 2
    Shapiro SD. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol 1998;10: 6028.
  • 3
    Westermarck J, Kähäri V-M. Regulation of matrix metalloproteinase expression in tumour invasion. FASEB J 1999;13: 78192.
  • 4
    Freije JM, Diez Itza I, Balbín M, et al. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 1994;269: 1676673.
  • 5
    Johansson N, Airola K, Grénman R, et al. Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am J Pathol 1997; 151: 499508.
  • 6
    Airola K, Johansson N, Kariniemi A-L, et al. Human collagenase-3 is expressed in malignant squamous epithelium of the skin. J Invest Dermatol 1997;109: 22531.
  • 7
    Johansson N, Vaalamo M, Grénman S, et al. Collagenase-3 (MMP-13) is expressed by tumour cells in invasive vulvar squamous cell carcinomas. Am J Pathol 1999; 154: 46980.
  • 8
    Airola K, Karonen T, Vaalamo M, et al. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. Br J Cancer 1999;80: 73343.
  • 9
    Nikkola J, Vihinen P, Vlaykova T, et al. High collagenase-1 expression correlates to favourable chemoimmunotherapy response in human metastatic melanoma. Melanoma Res 2001;11: 15766.
  • 10
    Uría JA, Balbín M, López JM, et al. Collagenase-3 (MMP-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor. Am J Pathol 1998; 153: 91101.
  • 11
    Boström PJ, Ravanti L, Reunanen N, et al. Expression of collagenase-3 (matrix metalloproteinase-13) in transitional cell carcinoma of the urinary bladder. Int J Cancer 2000;88: 41723.
  • 12
    Basset P, Bellocq JP, Wolf C, et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990;348: 699704.
  • 13
    Shapiro SD, Kobayashi DK, Ley TJ. Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J Biol Chem 1993;268: 238249.
  • 14
    Kerkelä E, Ala-aho R, Jeskanen L, et al. Expression of human macrophage metalloelastase (MMP-12) by tumour cells in skin cancer. J Invest Dermatol 2000;114: 11139.
  • 15
    Saarialho-Kere U, Crouch EC, Parks WC. Matrix metalloproteinase matrilysin is constitutively expressed in adult human exocrine epithelium. J Invest Dermatol 1995;105: 1906.
  • 16
    Wilson CL, Ouellette AJ, Satchell DP, et al. Regulation of intestinal α-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 1999;286: 1137.
  • 17
    Uria JA, Lopez-Otin C. Matrilysin-2, a new matrix metalloproteinase expressed in human tumours and showing the minimal domain organization required for secretion, latency and activity. Cancer Res 2000;60: 474551.
  • 18
    Seiki M. Membrane-type matrix metalloproteinases. APMIS 1999;107: 13743.
  • 19
    Okada A, Bellocq JP, Rouyer N, et al. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast and head and neck carcinomas. Proc Natl Acad Sci USA 1995;92: 27304.
  • 20
    Pendás AM, Knäuper V, Puente XS, et al. Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location and tissue distribution. J Biol Chem 1997; 272: 42816.
  • 21
    Velasco G, Pendás AM, Fueyo A, et al. Cloning and characterization of human MMP-23, a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members. J Biol Chem 1999; 274: 45706.
  • 22
    Westermarck J, Seth A, Kähäri VM. Differential regulation of interstitial collagenase (MMP-1) gene expression by ETS transcription factors. Oncogene 1997;14: 265160.
  • 23
    Pei D, Weiss SJ. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 1995;375: 2447.
  • 24
    Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000;1477: 26783.
  • 25
    Kähäri V-M, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 1999;31: 3445.
  • 26
    Wilson CL, Heppner KJ, Labosky PA, et al. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci USA 1997;94: 14027.
  • 27
    Masson R, Lefebvre O, Noel A, et al. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol 1998;140: 153541.
  • 28
    Itoh T, Tanioka M, Matsuda H, et al. Experimental metastasis is suppressed in MMP-9-deficient mice. Clin Exp Metastasis 1999;17: 17781.
  • 29
    Itoh T, Tanioka M, Yoshida H, et al. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998;58: 104851.
  • 30
    Ikebe T, Shinohara M, Takeuchi H, et al. Gelatinolytic activity of matrix metalloproteinase in tumour tissues correlates with invasiveness of oral cancer. Clin Exp Metastasis 1999;17: 31523.
  • 31
    Kodate M, Kasai T, Hashimoto H, et al. Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung. Pathol Int 1997;47: 4619.
  • 32
    Papathoma AS, Petraki C, Grigorakis A, et al. Prognostic significance of matrix metalloproteinase 2 and 9 in bladder cancer. Anticancer Res 2000;20: 200913.
  • 33
    Schmalfeldt B, Prechtel D, Harting K, et al. Increased expression of matrix metalloproteinases (mmp)-2, mmp-9 and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 2001;7: 2396404.
  • 34
    Maeta H, Oghi S, Terada T. Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas. Virchows Arch 2001;438: 1218.
  • 35
    Ara T, Fukuzawa M, Kusafuka T, et al. Immunohistochemical expression of MMP-2, MMP-9 and TIMP-2 in neuroblastoma: association with tumour progression and clinical outcome. J Pediatr Surg 1998;33: 12728.
  • 36
    Talvensaari A, Apaja-Sarkkinen M, Höyhtyä M, et al. Matrix metalloproteinase 2 immunoreactive protein appears early in cervical epithelial dedifferentiation. Gynecol Oncol 1999;72: 30611.
  • 37
    Davidson B, Goldberg I, Kopolovic J, et al. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma—a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol 1999;73: 37282.
  • 38
    Liokumovich P, Goldberg I, Davidson B, et al. Expression of metalloproteinases endometrial stromal sarcoma: immunohistochemical study using image analysis. J Clin Pathol 1999;52: 198202.
  • 39
    Du B, Wang P, Guo X, et al. Expression of membrane type 1-matrix metalloproteinase in laryngeal carcinoma. Pathol Oncol Res 1999;5: 2147.
  • 40
    Etoh T, Inoue H, Yoshikawa Y, et al. Increased expression of collagenase-3 (MMP-13) and MT1-MMP in eosophageal cancer is related to cancer aggressiveness. Gut 2000;47: 506.
  • 41
    Salmela MT, Karjalainen-Lindsberg ML, Puolakkainen P, et al. Upregulation and differential expression of matrilysin (MMP-7) and metalloelastase (MMP-12) and their inhibitors TIMP-1 and TIMP-3 in Barrett's oesophageal adenocarcinoma. Br J Cancer 2001;85: 38392.
  • 42
    Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 2000;36: 162130.
  • 43
    Biswas C, Zhang Y, DeCastro R, et al. The human tumour cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 1995;55: 4349.
  • 44
    Westermarck J, Li S, Jaakkola P, et al. Activation of fibroblast collagenase-1 expression by tumour cells of squamous cell carcinomas is mediated by p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase-2. Cancer Res 2000;60: 715662.
  • 45
    Cazorla M, Hernandez L, Nadal A, et al. Collagenase-3 expression is associated with advanced local invasion in human squamous cell carcinomas of the larynx. J Pathol 1998;186: 14450.
  • 46
    Ohashi K, Nemoto T, Nakamura K, et al. Increased expression of matrix metalloproteinase 7 and 9 and membrane type 1-matrix metalloproteinase in eosophageal squamous cell carcinomas. Cancer 2000;88: 22019.
  • 47
    Kurahara S, Shinohara M, Ikebe T, et al. Expression of MMPs, MT-MMP and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumour invasion and metastasis. Head Neck 1999;21: 62738.
  • 48
    Bando E, Yonemura Y, Endou Y, et al. Immunohistochemical study of MT-MMP tissue status in gastric carcinoma and correlation with survival analyzed by univariate and multivariate analysis. Oncol Rep 1998;5: 14838.
  • 49
    Kanayama H, Yokota K, Kurokawa Y, et al. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer 1998;82: 135966.
  • 50
    Rutter JL, Mitchell TI, Buttice G, et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 1998;58: 53215.
  • 51
    Ghilardi G, Biondi ML, Mangoni J, et al. Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness. Clin Cancer Res 2001;7: 23446.
  • 52
    Ye S, Dhillon S, Turner SJ, et al. Invasiveness of cutaneous malignant melanoma is influenced by matrix metalloproteinase 1 gene polymorphism. Cancer Res 2001;61: 12968.
  • 53
    Gojhi K, Fujimoto N, Komiyama T, et al. Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer 1996;78: 237987.
  • 54
    Westerlund A, Apaja-Sarkkinen M, Höyhtyä M, et al. Gelatinase A-immunoreactive protein in ovarian lesions—prognostic value in epithelial ovarian cancer. Gynecol Oncol 1999;75: 918.
  • 55
    Kuniyasu H, Ellis LM, Evans DB, et al. 1999. Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma. Clin Cancer Res 1999;5: 2533.
  • 56
    Koshiba T, Hosotani R, Wada M, et al. Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer 1998;15: 64250.
  • 57
    Yamamoto H, Itoh F, Adachi Y, et al. Messanger RNA expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human hepatocellular cancer. Jpn J Clin Oncol 1999;29: 5862.
  • 58
    Hara I, Miyake H, Hara S, et al. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder. J Urol 2001;165: 176972.
  • 59
    Moser PL, Kieback DG, Hefler L, et al. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2 and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage IB cervical cancer. Anticancer Res 1999;19: 43913.
  • 60
    Inoue T, Yashiro M, Nishimura S, et al. Matrix metalloproteinase-1 expression is a prognostic factor for patients with advanced gastric cancer. Int J Mol Med 1999;4: 737.
  • 61
    Väisänen A, Kallioinen M, von Dickhoff K, et al. Matrix metalloproteinase-2 (MMP-2) immunoreactive protein—a new prognostic marker in uveal melanoma? J Pathol 1999;188: 5662.
  • 62
    Yoshizaki T, Maruyama Y, Sato H, et al. Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma. Int J Cancer 2001;95: 4450.
  • 63
    Yamashita K, Azumano I, Mai M, et al. Expression and tissue localization of matrix metalloproteinase 7 (matrilysin) in human gastric carcinomas. Implications for vessel invasion and metastasis. Int J Cancer 1998;17: 18794.
  • 64
    Zeng ZS, Huang Y, Cohen AM, et al. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 1996;14: 313340.
  • 65
    Gokaslan ZL, Chintala SK, York JE, et al. Expression and role of matrix metalloproteinases MMP-2 and MMP-9 in human spinal column tumours. Clin Exp Metastasis 1998;16: 7218.
  • 66
    Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma. Breast Cancer Res Treat 1999;58: 28793.
  • 67
    Sunami E, Tsuno N, Osada T, et al. MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. Oncologist 2000;5: 10814.
  • 68
    Garbisa S, Scagliotti G, Masiero L, et al. Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res 1992;15: 45489.
  • 69
    Gojhi K, Fujimoto N, Hara I, et al. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int J Cancer 1998;79: 96101.
  • 70
    Slaton JW, Inoue K, Perrotte P, et al. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol 2001;158: 73543.
  • 71
    Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 2001;21: 110417.
  • 72
    Riedel F, Gotte K, Schwalb J, et al. 2000. Expression of 92-kDa type IV collagenase correlates with angiogenic markers and poor survival in head and neck squamous cell carcinoma. Int J Oncol 2000;17: 1099105.
  • 73
    Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2: 73744.
  • 74
    Hiraoka N, Allen E, Apel IJ, et al. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysis. Cell 1998;95: 36577.
  • 75
    Zhou Z, Apte SS, Soininen R, et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci USA 2000;97: 40527.
  • 76
    Shalinsky DR, Brekken J, Zou H, et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann NY Acad Sci 1999;878: 23670.
  • 77
    Gatto C, Rieppi M, Borsotti P, et al. BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity. Clin Cancer Res 1999;5: 36037.
  • 78
    Silvestre JS, Mallat Z, Tamarat R, et al. Regulation of matrix metalloproteinase activity in ischemic tissue by interleukin-10: role in ischemia-induced angiogenesis. Circ Res 2001;89: 25964.
  • 79
    Ferrante K, Winograd B, Canetta R. Promising new developments in cancer chemotherapy. Cancer Chemother Pharmacol 1999;43: S618.
  • 80
    Gingras D, Mousseau N, Gaumont-Leclerc M-F, et al. AE-941 (Neovastat) induces endothelial cell apoptosis through activation of caspase-3 activity. [abstract#3891] Proc AACR 92nd Annual Meeting 2001;42: 724.
  • 81
    Lokeshwar BL, Escatel E, Zhu B. Cytotoxic activity and inhibition of tumour cell invasion by derivatives of a chemically modified tetracycline CMT-3 (COL-3). Curr Med Chem 2001;8: 2719.
  • 82
    Thompson RW, Parks WC. Role of matrix metalloproteinases in abdominal aortic aneurysms. Ann NY Acad Sci 1996;800: 15774.
  • 83
    Patterson BC, Sang QA. 1997. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 1997;272: 288235.
  • 84
    Lijnen HR, Ugwu F, Bini A, et al. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry 1998;37: 4699702.
  • 85
    Dong Z, Kumar R, Yang X, et al. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997;88: 80110.
  • 86
    Brown PD. Ongoing trials with matrix metalloproteinase inhibitors. Exp Opin Invest Drugs 2000;9: 216777.
  • 87
    Kim YM, Jang JW, Lee OH, et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 2000;60: 54103.
  • 88
    Jurasz P, Sawicki G, Duszyk M, et al. Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: regulation by nitric oxide. Cancer Res 2001;61: 37682.
  • 89
    Kuittinen O, Savolainen ER, Koistinen P, et al. Gelatinase A and B (MMP-2, MMP-9) in leukaemia: MMP-2 may indicate a good prognosis in AML. Anticancer Res 1999;19: 4395400.
  • 90
    Nikkola J, Vihinen P, Vlaykova T, et al. High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. Int J Cancer 2002;97: 4328.
  • 91
    Arenas-Huertero FJ, Herrera-Goepfert R, Delgado-Chavez R, et al. Matrix metalloproteinases expressed in squamous cell carcinoma of the oral cavity: correlation with clinicopathologic features and neo-adjuvant chemotherapy response. J Exp Clin Cancer Res 1999;18: 27984.
  • 92
    Yamashita K, Mori M, Kataoka A, et al. The clinical significance of MMP-1 expression in eosophageal carcinoma. Br J Cancer 2001;84: 27682.
  • 93
    Murray I, Duncan ME, O′Neil P, et al. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996;2: 4612.
  • 94
    Ito T, Ito M, Shiozawa J, et al. Expression of the MMP-1 in human pancreatic carcinoma: relationship with prognostic factor. Mod Pathol 1999;12: 66974.
  • 95
    Grigioni WF, D'Errico A, Fortunato C, et al. Prognosis of gastric carcinoma revealed by interactions between tumour cells and basement membrane. Mod Pathol 1994;7: 2205.
  • 96
    Miyajima Y, Nakano R, Morimatsu M. Analysis of expression of matrix metalloproteinases-2 and -9 in hypopharyngeal squamous cell carcinoma by in situ hybridization. Ann Otol Rhinol Laryngol 1995;104: 67884.
  • 97
    Garzetti GG, Ciavattini A, Lucarini G, et al. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystadenocarcinomas: clinical and prognostic implications. Anticancer Res 1995;15: 2799804.
  • 98
    Passlick B, Sienel W, Seen-Hibler R, et al. Overexpression of matrix metalloproteinase 2 predicts unfavourable outcome in early-stage non-small cell lung cancer. Clin Cancer Res 2000;6: 39448.
  • 99
    Kanda K, Takahashi M, Murakami Y, et al. The role of the activated form of matrix metalloproteinase-2 in urothelial cancer. BJU Int 2000;86: 5537.
  • 100
    Walther MM, Kleiner DE, Lubensky IA, et al. Progelatinase A mRNA expression in cell lines derived from tumours in patients with metastatic renal cell carcinoma correlates inversely with survival. Urology 1997;50: 295301.
  • 101
    Talvensaari-Mattila A, Paakko P, Höyhtyä M, et al. Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer 1998;83: 115362.
  • 102
    Ring P, Johansson K, Höyhtyä M, et al. Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer—a predictor of tumour stage. Br J Cancer 1997;76: 80511.
  • 103
    Oberg A, Höyhtyä M, Tavelin B, et al. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res 2000;20: 108591.
  • 104
    Gojhi K, Fujimoto N, Fujii A, et al. Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases ratio in recurrence of urothelial cancer after complete resection. Cancer Res 1996;56: 31968.
  • 105
    Gojhi K, Fujimoto N, Ohkawa J, et al. Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer. Br J Cancer 1998;77: 6505.
  • 106
    Vuoristo MS, Kellokumpu-Lehtinen P, Parvinen LM, et al. Serum matrix metalloproteinase-2 as a prognostic marker in advanced cutaneous melanoma. Acta Oncol 2000;39: 8779.
  • 107
    Michael M, Babic B, Khokha R, et al. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol 1999;17: 18028.
  • 108
    Yamashita K, Mori M, Shiraishi T, et al. Clinical significance of matrix metalloproteinase-7 expression in esophageal carcinoma. Clin Cancer Res 2000;6: 116974.
  • 109
    Yamamoto H, Itoh F, Iku S, et al. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. J Clin Oncol 2001;15: 111827.
  • 110
    Zucker S, Hymowitz M, Conner C, et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann NY Acad Sci 1999;30: 21227.
  • 111
    Nelson AR, Fingleton B, Rotherberg ML, et al. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18: 113549.
  • 112
    Beattie GJ, Smyth JF. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin Cancer Res 1998;4: 1899902.
  • 113
    Kruger A, Soeltl R, Sopov I, et al. Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. Cancer Res 2001;61: 12725.
  • 114
    Macaulay VM, O′Byrne KJ, Saunders MP, et al. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res 1999;5: 51320.
  • 115
    Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001;93: 17893.
  • 116
    Wojtowicz-Praga S, Torri J, Johnson M, et al. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol 1998;16: 21506.
  • 117
    Tierney GM, Griffin NR, Stuart RC, et al. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. Eur J Cancer 1999;35: 5638.
  • 118
    Primrose JN, Bleiberg H, Daniel F, et al. Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcioembryonic antigen. Br J Cancer 1999;79: 50914.
  • 119
    Rosemurgy A, Harris J, Langleben A, et al. Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Am J Clin Oncol 1999;22: 24752.
  • 120
    Miller KD, Gradishar WJ, Schuchter LM, et al. A randomized phase II pilot trial of adjuvant marimastat (MAR) in patients with early breast cancer. [abstract #369] Proc ASCO 2000;19: 96a.
  • 121
    Bramhall SR, Rosemurgy A, Brown PD, et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer. J Clin Oncol 2001;19: 344755.
  • 122
    British Biotech. Results of marimastat Study 186 in patients with advanced ovarian cancer. Press release, 2000;September 26.
  • 123
    Shepherd FA, Giaccone G, Depruyne C, et al. Randomized double-blind placebo-controlled trial of marimastat in patients with small cell lung cancer (SCLC) following response to first-line chemotherapy: an NCIC-CTG and EORTC study [abstract #11]. Proc ASCO 2001;20: 4a.
  • 124
    Phuphanich S, Levin VA, Yung WK, et al. A multicenter, randomized, double-blind, placebo (PB) controlled trial of marimastat (MT) in patients with glioblastoma multiforme (GMB) or gliosarcoma (GS) following completion of conventional, first-line treatment. [abstract #205] Proc ASCO 2001;20: 52a.
  • 125
    Fielding J, Scholefield J, Stuart R, et al. A randomized double-blind placebo-controlled study of Marimastat in patients with inoperable gastric adenocarcinoma. [abstract #929] Proc ASCO 2000;19: 240a.
  • 126
    British Biotech. Marimastat update. Press release, 2001;May 2.
  • 127
    Rugo HS, Budman D, Vogel C, et al. Phase II study of the matrix metalloproteinase inhibitor prinomastat in patient with progressive breast cancer. [abstract #187] Proc ASCO 2001;20: 48a.
  • 128
    Ahmann FR, Saad F, Mercier R, et al. Interim results of a phase III study of the matrix metalloproteinase inhibitor prinomastat in patients having metastatic, hormone refractory prostate cancer (HRPC). [abstract #692] Proc ASCO 2001;20: 174a.
  • 129
    Pfizer. Pfizer discontinues phase III trials of prinomastat in advanced cancers but continues multiple phase II trials. Press release, 2001;August 4.
  • 130
    Smylie M, Mercier R, Aboulafia D, et al. Phase III study of the matrix metalloproteinase (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer (NSCLC) [abstract #1226]. Proc ASCO 2001;20: 307a.
  • 131
    Agouron Pharmaceuticals. Agouron announces pilot Phase II clinical trial of its matrix metalloproteinase inhibitor prinomastat in glioblastoma multiforme. Press release, 1999;November 22.
  • 132
    Rowinsky EK, Humphrey R, Hammond LA, et al. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J Clin Oncol 2000;18: 17886.
  • 133
    Moore MJ, Hamm J, Eisenberg P, et al. A comparison between gemcitabine (GEM) and the matrix metalloproteinase (MMP) inhibitor BAY12-9566 (9566) in patients (pts) with advanced pancreatic cancer. [abstract #930] Proc ASCO 2000;19: 240a.
  • 134
    PR Newswire. Bayer halts clinical trials evaluating MMPI. PR Newswire 1999;September 24.
  • 135
    Hirte HW, Vergote IB, Jeffrey JR, et al. 2001. An international multicentre phase III study of BAY 12-9566 (BAY) versus placebo in patients (pts) with advanced ovarian cancer (OVCA) responsive to primary surgery/paclitaxel + platinum containing chemotherapy (CT). [abstract #843] Proc ASCO 2001;20: 211a.
  • 136
    National Cancer Institute. http://cancertrials.nci.nih.gov/news
  • 137
    Levitt NC, Eskens FA, O′Byrne KJ, et al. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res 2001;7: 191222.
  • 138
    Escudier B, Patenaude F, Bukowski R, et al. AE-941 (Neovastat) shows an excellent safety profile and appears beneficial in patients with solid tumours: rationale for the initiation of 2 phase III clinical trials. [abstract #2916] Proc AACR 92nd Annual Meeting 2001;42: 542.
  • 139
    Aeterna Laboratories. www.aeterna.com
  • 140
    CollaGenex Pharmaceuticals. Angiogenesis inhibitor shows early promise in treatment of Kaposi′s Sarcoma. News Release 2000;May 5.
  • 141
    Rudek MA, Figg WD, Dyer V, et al. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J Clin Oncol 2001;19: 58492.
  • 142
    Munoz-Mateu M, de′ Grafenried L, Eckhardy S, et al. Pharmacodynamic studies of Col-3, a novel matrix metalloproteinase inhibitor, in patients with advanced cancer. [abstract #302] Proc ASCO 2001;20: 76a.
  • 143
    Rudek MA, Horne M, Figg WD, et al. Reversible sideroplastic anemia associated with the tetracycline analogue COL-3. Am J Hematol 2001;67: 513.
  • 144
    Teronen O, Heikkilä P, Konttinen YT, et al. MMP inhibition and downregulation by biphosphonates. Ann NY Acad Sci 1999;878: 45365.
  • 145
    Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996;335: 178591.
  • 146
    Paterson AH. Adjuvant biphosphonate therapy: the future. Semin Oncol 2001; 4S11; 815.
  • 147
    Stearns ME, Wang M. Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice. Clin Exp Metastasis 1998;16: 693702.
  • 148
    Farina AR, Tacconelli A, Teti A, et al. Tissue inhibitor of metalloproteinase-2 protection of matrix metalloproteinase-2 from degradation by plasmin is reversed by divalent cation chelator EDTA and the biphosphonate alendronate. Cancer Res 1998;58: 295760.
  • 149
    Yip D, Ahmad A, Karapetis CS, et al. Matrix metalloproteinase inhibitors: applications in oncology. Invest New Drugs 1999;17: 38799.
  • 150
    Brown PD. Clinical studies with matrix metalloproteinase inhibitors. APMIS 1999;107: 17480.
  • 151
    Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000;19: 664250.
  • 152
    Jaalinoja J, Herva R, Korpela M, et al. Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms. J Neurooncol 2000;46: 8190.
  • 153
    Chenard MP, O'Siorain L, Shering S, et al. High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int J Cancer 1996;69: 44851.
  • 154
    Zucker S, Lysik RM, Zarrabi MH, et al. 1993. M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 1993;53: 1406.
  • 155
    Sier CF, Kubben FJ, Ganesh S, et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996;74: 4137.
  • 156
    Allgayer H, Babic R, Beyer BC, et al. 1998. Prognostic relevance of MMP-2 (72-kD collagenase IV) in gastric cancer. Oncology 1998;55: 15260.
  • 157
    Mori M, Mimori K, Shiraishi T, et al. Analysis of MT1-MMP and MMP2 expression in human gastric cancers. Int J Cancer 1997;20: 31621.
  • 158
    Määttä M, Soini Y, Liakka A, et al. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9 and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumour progression and clinical prognosis. Clin Cancer Res 2000;6: 272634.
  • 159
    Ylisirniö S, Höyhtyä M, Turpeenniemi-Hujanen T. Serum matrix metalloproteinases-2, -9 and tissue inhibitors of metalloproteinases-1, -2 in lung cancer—TIMP-1 as a prognostic marker. Anticancer Res 2000;20: 13116.
  • 160
    Herbst RS, Yano S, Kuniyasu H, et al. 2000. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Clin Cancer Res 2000;6: 7907.
  • 161
    Cox G, Jones JL, O′Byrne KJ. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res 2000;6: 234955.
  • 162
    Väisänen A, Kallioinen M, Taskinen PJ, et al. 1998. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol 1998;186: 518.
  • 163
    Sakakibara M, Koizumi S, Saikawa Y, et al. Membrane-type matrix metalloproteinase-1 expression and activation of gelatinase A as prognostic markers in advanced pediatric neuroblastoma. Cancer 1999;85: 2319.
  • 164
    Murray I, Duncan ME, O′Neil P, et al. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 1998;185: 25661.
  • 165
    Davidson B, Goldberg I, Gotlieb WH, et al. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian cancer. Clin Exp Metastasis 1999;17: 799808.